New Immunotherapy Approaches Strengthening Immunity: T Cell Therapy for Blood Cancers

Alongside immune checkpoint inhibitors, which we call conventional immunotherapies, scientists have begun intensive research into T cell-centered approaches. T cells are among the immune system’s most important components, and specialized T cells actively fight cancer cells.
A new immunotherapy antibody called Blinatumomab binds two different proteins on white blood cells: CD19 on B cells and CD3 on T cells. It thereby brings cancer-killing T cells into contact with malignant B cell leukemia cells.
Early results of a new study showed complete remission after Blinatumomab in nearly 1/3 of patients with recurrent ALL (acute lymphocytic leukemia) or resistance to standard treatment. Responses lasted long in many patients (more than 6 months). Their ALL was a rare, aggressive, rapidly developing Philadelphia chromosome-negative precursor B cell ALL in which bone marrow produces excessive immature white cells. Based on the results, in December 2014 the FDA approved Blinatumomab for this difficult disease.
Further studies are needed to show whether Blinatumomab extends survival compared with standard chemotherapy. Nevertheless, immunotherapy clearly has a role in ALL. Future studies will investigate its use with other treatments and at disease onset.
Another new strategy is chimeric antigen receptor (CAR) T cell therapy. Patients’ T cells are collected, reprogrammed in the laboratory and reinfused. They produce proteins that readily find and attack cancer cells. Preliminary results suggest difficult blood cancers (leukemias) may benefit. For example, CD-19-directed CAR T cells are programmed to attack malignant B cells carrying CD19.
In a study of adults and children with recurrent ALL, of 30 patients, 27 achieved complete remission after treatment, lasting long and continuing for 2 years. Overall, 78% receiving CAR T cells survived 6 months.
In another study, of 15 patients with chemotherapy-resistant diffuse large B cell lymphoma (DLBCL) and other blood cancers, 12 responded to CD-19-directed CART T cells and cancer disappeared completely in 8.
Although promising, these findings need further research. Studies were small, with few volunteers whose cancers were difficult to treat. Therefore, CAR T cell therapy’s future widespread use remains uncertain. Side effects included fever, low blood pressure and delirium (loss of perception and consciousness, confusion).
Sources
2. US Food and Drug Administration: FDA approves Blincyto to treat a rare form of acute lymphoblastic leukemia. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm425549.htm
3. Maude SL, Frey N, Shaw PA, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507-1517, 2014
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.